The Impact of Medicare Part D on Medication Treatment of Hypertension

Overview

Journal Health Serv Res

Specialty Health Services

Date 2010 Oct 1

PMID 20880045

Citations 16

Authors

Yuting Zhang

Julie M Donohue

Judith R Lave

Walid F Gellad

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate Medicare Part D's impact on use of antihypertensive medications among seniors with hypertension.

Data Sources: Medicare-Advantage plan pharmacy data from January 1, 2004 to December 12, 2007 from three groups who before enrolling in Part D had no or limited drug benefits, and a comparison group with stable employer-based coverage.

Study Design: Pre-post intervention with a comparison group design was used to study likelihood of use, daily counts, and substitutions between angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers (ARBs).

Principal Findings: Antihypertensive use increased most among those without prior drug coverage: likelihood of use increased (odds ratio = 1.40, 95 percent confidence interval [CI] 1.25-1.56), and daily counts increased 0.29 (95 percent CI 0.24-0.33). Proportion using ARBs increased from 40 to 46 percent.

Conclusions: Part D was associated with increased antihypertensive use and use of ARBs over less expensive alternatives.

Citing Articles

Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021.

Jacobs J, Rodgers A, Bellows B, Hernandez I, Wang N, Derington C Hypertension. 2024; 81(11):2307-2317.

PMID: 39229724 PMC: 11483193. DOI: 10.1161/HYPERTENSIONAHA.124.23509.

Association of Economic Policies With Hypertension Management and Control: A Systematic Review.

Zhang D, Lee J, Pollack L, Dong X, Taliano J, Rajan A JAMA Health Forum. 2024; 5(2):e235231.

PMID: 38334993 PMC: 10858400. DOI: 10.1001/jamahealthforum.2023.5231.

Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D.

Alpert A, Lakdawalla D, Sood N J Public Econ. 2023; 221.

PMID: 37275770 PMC: 10237358. DOI: 10.1016/j.jpubeco.2023.104860.

Pharmaceutical policies: effects of regulating drug insurance schemes.

Pantoja T, Penaloza B, Cid C, Herrera C, Ramsay C, Hudson J Cochrane Database Syst Rev. 2022; 5:CD011703.

PMID: 35502614 PMC: 9062704. DOI: 10.1002/14651858.CD011703.pub2.

Medicare Part D's Effects on Drug Utilization and Out-of-Pocket Costs: A Systematic Review.

Park Y, Martin E Health Serv Res. 2016; 52(5):1685-1728.

PMID: 27480577 PMC: 5583296. DOI: 10.1111/1475-6773.12534.

References

Yin W, Basu A, Zhang J, Rabbani A, Meltzer D, Alexander G . The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008; 148(3):169-77. DOI: 10.7326/0003-4819-148-3-200802050-00200. View

Pope G, Kautter J, Ellis R, Ash A, Ayanian J, Lezzoni L . Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev. 2004; 25(4):119-41. PMC: 4194896. View

Hsu J, Price M, Huang J, Brand R, Fung V, Hui R . Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006; 354(22):2349-59. DOI: 10.1056/NEJMsa054436. View

. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24):3255-64. View

Egan B, Zhao Y, Axon R . US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010; 303(20):2043-50. DOI: 10.1001/jama.2010.650. View

Ketcham J, Simon K . Medicare Part D's effects on elderly patients' drug costs and utilization. Am J Manag Care. 2008; 14(11 Suppl):SP14-22. View

Zhang Y, Donohue J, Lave J, ODonnell G, Newhouse J . The effect of Medicare Part D on drug and medical spending. N Engl J Med. 2009; 361(1):52-61. PMC: 2859614. DOI: 10.1056/NEJMsa0807998. View

Huskamp H, Deverka P, Epstein A, Epstein R, McGuigan K, Frank R . The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003; 349(23):2224-32. DOI: 10.1056/NEJMsa030954. View

Matchar D, McCrory D, Orlando L, Patel M, Patel U, Patwardhan M . Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2007; 148(1):16-29. DOI: 10.7326/0003-4819-148-1-200801010-00189. View

10.

Zhang J, Yin W, Sun S, Alexander G . The impact of the Medicare Part D prescription benefit on generic drug use. J Gen Intern Med. 2008; 23(10):1673-8. PMC: 2533371. DOI: 10.1007/s11606-008-0742-6. View

11.

Kunz R, Friedrich C, Wolbers M, Mann J . Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2007; 148(1):30-48. DOI: 10.7326/0003-4819-148-1-200801010-00190. View

12.

Schneeweiss S, Patrick A, Pedan A, Varasteh L, Levin R, Liu N . The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff (Millwood). 2009; 28(2):w305-16. PMC: 2683877. DOI: 10.1377/hlthaff.28.2.w305. View